8 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Showing 8 of 8 clinical reviews.
A clinical breakdown of the legal status of compounded Adderall XR (mixed amphetamine salts), including FDA shortage declarations, 503A/503B pharmacy rules, DEA scheduling, and what the end of the shortage means for patients.
A detailed review of Adderall XR (mixed amphetamine salts) safety signals in the FDA Adverse Event Reporting System (FAERS), including cardiovascular, psychiatric, and pediatric findings.
A complete timeline of Adderall XR FDA approval, label revisions, boxed warnings, and post-market safety surveillance from 1996 through 2026.
A clinician-reviewed guide to Adderall XR (mixed amphetamine salts) regulatory status worldwide, covering FDA approval history, DEA scheduling, EMA classification, and current label safety information.
A complete timeline of Adderall XR (mixed amphetamine salts) FDA label changes from 2020 through 2026, covering cardiovascular warnings, shortage declarations, pregnancy data revisions, and abuse-deterrent language updates.
A complete review of Adderall XR FDA approval history, patent litigation, label changes, and post-market safety findings, with primary-source citations throughout.
A clinical overview of the Adderall XR regulatory history, current pipeline competitors, and next-generation ADHD stimulant formulations under FDA review or in late-stage trials.
How the FDA and EMA differ in their regulatory handling of Adderall XR (mixed amphetamine salts), including approval history, labeling, safety surveillance, and what European patients use instead.